Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen

Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen

Summary

GBI Research, a leading business intelligence provider, has released its latest research, “Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen”, which provides insights into the global contraceptives market and market forecasts until 2018. The report provides an in-depth analysis of the most commonly used contraceptives, such as oral, topical, and injectable contraceptives, and devices such as intrauterine devices, condoms, and vaginal rings. The report also examines the usage patterns and annual cost of usage for these segments. It also includes insights into the contraceptives R&D product pipeline and explores the competitive landscape, including major companies in the contraceptives market. Finally, the report also includes analysis of the mergers and acquisitions (M&A) and licensing agreements that have taken place in the global contraceptives market.

The contraceptives market is growing, and more than 90 million people from seven major markets used them in 2011, with more than 24 million people having used them in the US alone. The user population is expected to grow gradually during the forecast period and reach more than 94 million in 2018.

According to GBI Research’s analysis, in 2011, the contraceptives market was worth $10.2 billion, indicating a Compounded Annual Growth Rate (CAGR) of 2.7% between 2004 and 2011. By 2018, the market is expected to reach $11.8 billion, growing at a CAGR of 2.1%. The launch of the FC patch, AG200-15, Savvy Gel, LNG 20, Pill-Plus and some key products in the late stage pipeline combined with increasing awareness are expected to drive the market.

The annual cost of usage for contraceptives was $113 in 2011, which grew from $104 in 2004 at a CAGR of 1.2%. This is expected to grow to $125 in 2018, at a CAGR of 1.4% between 2011 and 2018. The growth rate can be attributed to factors such as the expected patent expiry of Mirena and Yaz. In the forecast period, CSD500, a condom manufactured by Futura Medical and licensed to Reckitt and Benckiser, is expected to strengthen the condom market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

Scope

- Data and analysis on the contraceptives market in leading geographies: the US, the UK, Germany, France, Italy, Spain and Japan; along with their reach in emerging markets.
- Annualized market data for oral contraceptives, topical contraceptives, injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market from 2004–2011, with forecasts to 2018.
- Market data on the therapeutic landscape, which covers oral, topical and injectable contraceptives, and includes market revenues, treatment usage patterns and the annual cost of usage.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the contraceptives market, which includes companies such as Bayer, Merck, Church & Dwight, Warner Chilcott Company, and Pfizer.
- Key M&A activities and licensing agreements that took place from 2008–2012 in the contraceptives market.

Reasons to buy

- Align your product portfolio to markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more specifically-tailored country strategy through understanding of the key drivers and barriers in the contraceptives market of all the major countries.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9
2 Contraceptives Market to 2018 - Introduction 10
3 Contraceptives Market to 2018 - Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for Contraceptives Market 12
3.2.1 Revenues 12
3.2.2 Annual Cost of Usage for Contraceptives 15
3.2.3 Contraceptive Users 16
3.3 Drivers and Barriers for the Contraceptives Market 17
3.3.1 Drivers for Contraceptives Therapeutics Market 17
3.3.2 Barriers for Contraceptives 18
4 Contraceptives Market to 2018 - Geographical Landscape 19
4.1 The US 19
4.1.1 Revenue 19
4.1.2 Annual Cost of Usage for Contraceptives 20
4.1.3 Contraceptive Users 21
4.2 Top Five Countries of Europe 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Usage for Contraceptives 23
4.2.3 Contraceptive Users 24
4.3 Japan 25
4.3.1 Revenue 25
4.3.2 Annual Cost of Usage for Contraceptives 26
4.3.3 Contraceptive Users 27
5 Contraceptives Market to 2018 - Therapeutic Landscape 28
5.1 Oral Contraceptives 28
5.1.1 Introduction 28
5.1.2 Combined Hormonal Contraception 29
5.1.3 Oral Contraceptive Historic Trends 29
5.1.4 Recently Approved Combined Oral Contraceptives 29
5.1.5 Revenue 30
5.1.6 Annual Cost of Usage 33
5.1.7 Oral Contraceptive Users 34
5.2 Injectables 35
5.2.1 Introduction 35
5.2.2 Revenue 35
5.2.3 Annual Cost of Usage 39
5.2.4 Injectable Contraceptive Users 40
5.3 Topical Contraceptives 41
5.3.1 Introduction 41
5.3.2 Revenue 42
5.3.3 Annual Cost of Usage 45
5.3.4 Topical Contraceptive Users 46
6 Contraceptives Market to 2018 - Devices Landscape 47
6.1 Vaginal Ring 47
6.1.1 Introduction 47
6.1.2 Revenue 47
6.1.3 Geographical Segmentation 49
6.1.4 Annual Cost of Usage 51
6.1.5 Vaginal Ring Users 52
6.2 Intrauterine Device 53
6.2.1 Introduction 53
6.2.2 Revenue 53
6.2.3 Geographical Segmentation 55
6.2.4 Annual Cost of Usage 57
6.2.5 IUDs Users 58
6.3 Condoms 59
6.3.1 Introduction 59
6.3.2 Revenue 59
6.3.3 Geographical Segmentation 60
6.3.4 Annual Cost of Usage 62
6.3.5 Condom Users 63
7 Emerging Markets 64
7.1 China 64
7.2 Australia 65
7.3 India 66
8 Contraceptives Market to 2018 - Pipeline Analysis 67
8.1 Introduction 67
8.2 Profiles of Promising Drugs in the Global Contraceptives Market 68
8.2.1 AG200-15 68
8.2.2 FC Patch Low 68
8.2.3 Pill-Plus 69
9 Contraceptives Market to 2018 - Competitive Landscape 70
9.1 Market Share Analysis - Contraceptives Market 70
9.2 Drug Profile of Major Marketed Contraceptives 71
9.2.1 Yaz/Yasmin 71
9.2.2 Mirena 71
9.2.3 Nuvaring 71
9.3 Competitive Profiling 72
9.3.1 Bayer 72
9.3.2 Merck 73
9.3.3 Church & Dwight 74
9.3.4 Warner Chilcott Company, Inc. 75
9.3.5 Pfizer Inc. 76
10 Contraceptives Market to 2018 - Strategic Consolidations 77
10.1 Mergers and Acquisitions 77
10.1.1 Major M&A Deals 77
10.1.2 Licensing Agreements 77
10.1.3 Deals by Geography 78
10.1.4 Major Licensing Agreements 78
10.1.5 Co-development 79
11 Contraceptives Market to 2018 - Appendix 80
11.1 Market Definitions 80
11.2 Abbreviations 80
11.3 Bibliography 80
11.4 Research Methodology 81
11.4.1 Coverage 82
11.4.2 Secondary Research 82
11.4.3 Primary Research 82
11.4.4 Expert Panel Validation 83
11.5 Therapeutic Landscape 83
11.5.1 Epidemiology-Based Forecasting 83
11.5.2 Market Size by Geography 84
11.6 Geographical Landscape 84
11.7 Pipeline Analysis 84
11.8 Competitive Landscape 84
11.9 Contact Us 85
11.10 Disclaimer 85